

# Pharmacokinetic Study of Single-Dose Modified Release Glipizide in Healthy Volunteers

NCT05159427

---

Status	RECRUITING
Phase	Phase 1
Sponsor	University of Michigan
Enrollment	40 participants

## Key Eligibility Criteria

---

### Inclusion (4)

- Male or female adults age 18 to 55 years with BMI ranging from 18.5 to 35 kg/m2 inclusive
- Ability to independently provide an informed consent
- Demonstrate the ability to swallow a multivitamin pill that mimics a SmartPill capsule
- Negative serum pregnancy test (for women of child-bearing potential)

### Exclusion (43)

- Unable to independently provide an informed consent for themselves or mentally incapacitated.
- Physical disability (including blindness or deafness) that requires special arrangements.
- Significant clinical illness, including cardiovascular disease, neurological disease, organ failure, or malignancy in the opinion of the investigator
- Any surgical procedure within 3 weeks prior to screening
- History and/or presence of severe seasonal allergies or severe allergic diseases including drug allergies, food allergies and allergy against the SmartPill® device
- ... and 38 more (see full listing online)

## Locations (1 total)

---

University of Michigan, Ann Arbor, Michigan, United States